Cocrystal Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cocrystal Pharma
COCP Stock  USD 1.11  0.00  0.00%   
Analyzing historical trends in various income statement and balance sheet accounts from Cocrystal Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cocrystal Pharma's valuation are summarized below:
Gross Profit
-5.5 M
Market Capitalization
15.2 M
Enterprise Value Revenue
17.8912
Revenue
510 K
Earnings Share
(0.93)
There are currently one hundred twenty fundamental signals for Cocrystal Pharma that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Cocrystal Pharma's prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/08/2026, Market Cap is likely to drop to about 51.3 M. In addition to that, Enterprise Value is likely to drop to about 2 M

Cocrystal Pharma Total Revenue

5.43 Million

Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 170.9 K, Interest Expense of 1.7 K or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 33.23, Dividend Yield of 0.0 or PTB Ratio of 2.36. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Build AI portfolio with Cocrystal Stock
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Cocrystal Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.7 M15.5 M64.6 M
Pretty Stable
Total Current Liabilities2.7 M2.2 M3.9 M
Slightly volatile
Accounts Payable1 M1.8 M964.8 K
Slightly volatile
Cash11.9 M11.3 M12.8 M
Slightly volatile
Non Current Assets Total2 M2.2 M50 M
Slightly volatile
Cash And Short Term Investments12 M11.3 M12.9 M
Slightly volatile
Common Stock Total Equity152.4 K81.7 K143.9 K
Pretty Stable
Common Stock Shares Outstanding12.3 M11.7 M4.5 M
Slightly volatile
Liabilities And Stockholders Equity14.7 M15.5 M64.6 M
Pretty Stable
Other Stockholder Equity414.1 M394.4 M221.1 M
Slightly volatile
Total Liabilities3.4 M3.5 M23.9 M
Slightly volatile
Total Current Assets13.5 M13.3 M14.6 M
Slightly volatile
Common Stock8.6 K9 K116.6 K
Slightly volatile
Other Current Liabilities500.2 K526.5 K2.4 M
Slightly volatile
Property Plant And Equipment Net2.2 M2.1 M1.2 M
Pretty Stable
Other Current Assets324.4 K580.8 K577.3 K
Slightly volatile
Property Plant And Equipment Gross4.6 M4.3 M1.9 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.6 M1.9 M
Slightly volatile
Non Current Liabilities Total1.3 M1.4 M34.6 M
Slightly volatile
Inventory64.1 K67.5 K354 K
Slightly volatile
Short Term Debt257.4 K270.9 K2.1 M
Slightly volatile
Intangible Assets80.6 M62 M67.3 M
Very volatile
Current Deferred Revenue897.6 K647.1 K1.1 M
Slightly volatile
Capital Surpluse215.9 M341.9 M200 M
Slightly volatile
Other Liabilities23.1 M15.6 M12.8 M
Slightly volatile
Long Term Debt861 K906.3 K22.8 M
Slightly volatile
Short Term Investments24.8 K26.1 K600.9 K
Slightly volatile
Long Term Debt Total12 K12.6 K22.3 M
Slightly volatile
Deferred Long Term Liabilities87.8 M48.5 M99.6 M
Slightly volatile
Long Term Investments1.9 M2.1 M2.3 M
Slightly volatile
Short and Long Term Debt861 K906.3 K3.4 M
Slightly volatile
Preferred Stock Total Equity142.6 M160.4 M175.1 M
Slightly volatile
Property Plant Equipment640.6 K708.4 K526.9 K
Slightly volatile
Net Invested Capital8.1 M8.6 M68.6 M
Slightly volatile
Net Working Capital10 M10.5 M11.7 M
Slightly volatile
Capital Lease Obligations2.2 M2.1 M772.9 K
Slightly volatile
Capital Stock8.6 K9 K30.6 K
Pretty Stable
Non Current Liabilities Other366.4 K341.1 K469 K
Slightly volatile

Cocrystal Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.3 M6.1 M4.7 M
Slightly volatile
Selling And Marketing Expenses8.9 M8.5 M6.3 M
Slightly volatile
Other Operating Expenses26.4 M20.6 M28.2 M
Very volatile
Cost Of Revenue15.1 M14.4 M6.3 M
Slightly volatile
Total Operating Expenses5.8 M6.1 M21.6 M
Very volatile
Research Development21.8 M14.4 M18.5 M
Very volatile
Preferred Stock And Other Adjustments3.3 M3.7 M4.1 M
Slightly volatile
Interest Income202.6 K213.3 K3.6 M
Slightly volatile
Reconciled Depreciation325.7 K512.9 K230.3 K
Slightly volatile
Non Recurring36.9 M41.5 M45.3 M
Slightly volatile

Cocrystal Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow31.9 M30.4 M14.6 M
Slightly volatile
End Period Cash Flow11.9 M11.4 M12.8 M
Slightly volatile
Stock Based Compensation549.8 K578.7 K1.9 M
Slightly volatile
Sale Purchase Of Stock43.2 M41.2 M18.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio33.2334.981.1 K
Slightly volatile
Days Sales Outstanding1101161.5 K
Slightly volatile
Average Payables259.8 K432.1 K436.8 K
Pretty Stable
Stock Based Compensation To Revenue0.360.382.8634
Pretty Stable
EV To Sales19.4720.491 K
Slightly volatile
Inventory Turnover4.93.74.0451
Slightly volatile
Days Of Inventory On Hand69.110293.6296
Slightly volatile
Payables Turnover0.08930.0941.2446
Slightly volatile
Sales General And Administrative To Revenue2.873.0216.6643
Slightly volatile
Average Inventory954.5 K949.4 K850.3 K
Pretty Stable
Research And Ddevelopement To Revenue2.682.8290.2518
Slightly volatile
Capex To Revenue0.10.110.3803
Pretty Stable
Cash Per Share0.830.873.4796
Pretty Stable
Days Payables Outstanding4.9 K5.1 K14.7 K
Very volatile
Income Quality1.031.084.7043
Pretty Stable
Intangibles To Total Assets0.210.220.5104
Slightly volatile
Current Ratio5.824.298.1191
Slightly volatile
Receivables Turnover3.964.178.0146
Slightly volatile
Capex Per Share9.0E-49.0E-40.3701
Slightly volatile
Average Receivables901.6 K780.9 K731.2 K
Pretty Stable
Revenue Per Share0.460.4816.1306
Slightly volatile
Interest Debt Per Share0.190.27.7138
Slightly volatile
Debt To Assets0.210.150.1848
Slightly volatile
Operating Cycle1241301.5 K
Slightly volatile
Days Of Payables Outstanding4.9 K5.1 K14.7 K
Very volatile
Ebt Per Ebit1.331.131.254
Slightly volatile
Total Debt To Capitalization0.170.180.4071
Slightly volatile
Quick Ratio5.784.298.0828
Slightly volatile
Net Income Per E B T0.961.150.97
Pretty Stable
Cash Ratio5.413.657.5211
Slightly volatile
Days Of Inventory Outstanding69.110293.6296
Slightly volatile
Days Of Sales Outstanding1101161.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.151.1312
Slightly volatile
Fixed Asset Turnover3.12.133.0069
Pretty Stable
Debt Ratio0.210.150.1848
Slightly volatile
Price Sales Ratio33.2334.981.1 K
Slightly volatile
Asset Turnover0.04060.04270.4062
Slightly volatile

Cocrystal Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap51.3 M54 M98.4 M
Pretty Stable
Enterprise Value2 M2.1 M70.5 M
Slightly volatile

Cocrystal Fundamental Market Drivers

Cocrystal Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue647.1 K897.6 K
Cost Of Revenue14.4 M15.1 M
Stock Based Compensation To Revenue 0.38  0.36 
Sales General And Administrative To Revenue 3.02  2.87 
Research And Ddevelopement To Revenue 2.82  2.68 
Capex To Revenue 0.11  0.10 
Revenue Per Share 0.48  0.46 
Ebit Per Revenue(5.47)(5.75)

Pair Trading with Cocrystal Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cocrystal Stock

  0.64ACB Aurora CannabisPairCorr

Moving against Cocrystal Stock

  0.65GSK GlaxoSmithKline PLC ADRPairCorr
  0.65JNJ Johnson JohnsonPairCorr
  0.61MRK Merck Company Sell-off TrendPairCorr
  0.58AZN AstraZeneca PLC ADRPairCorr
  0.53BMY Bristol Myers Squibb Aggressive PushPairCorr
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY